Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This study is a prospective, single-arm, dose-escalation exploratory clinical trial to investigate the safety, tolerability and preliminary efficacy of REGEND007 stem cell preparation administered by intravenous infusion in the treatment of idiopathic pulmonary fibrosis (IPF), with a follow-up period of 12 weeks.
Epistemonikos ID: cea8aae6d57b712073a22489776386def604574b
First added on: Jan 23, 2026